LENZ

Company Overview — What Does LENZ Therapeutics, Inc. Do?

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. LENZ Therapeutics, Inc. (LENZ) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Evert B. Schimmelpennink and employs approximately 110 people. With a market capitalization of $293M, LENZ is one of the notable companies in the Healthcare sector.

LENZ Therapeutics, Inc. (LENZ) Stock Rating — Avoid (April 2026)

As of April 2026, LENZ Therapeutics, Inc. receives a Avoid rating with a composite score of 20.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LENZ ranks #4,348 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LENZ Therapeutics, Inc. ranks #798 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LENZ Stock Price and 52-Week Range

LENZ Therapeutics, Inc. (LENZ) currently trades at $9.04. The stock lost $0.25 (2.7%) in the most recent trading session. The 52-week high for LENZ is $50.40, which means the stock is currently trading -82.1% from its annual peak. The 52-week low is $11.32, putting the stock -20.1% above its annual trough. Recent trading volume was 207K shares, suggesting relatively thin trading activity.

Is LENZ Overvalued or Undervalued? — Valuation Analysis

LENZ Therapeutics, Inc. (LENZ) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.07x, versus the sector average of 2.75x. The price-to-sales ratio is 17.40x, compared to 1.66x for the average Healthcare stock.

At current multiples, LENZ Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

LENZ Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

LENZ Therapeutics, Inc. (LENZ) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -19.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -18.4% versus the sector average of -33.1%.

On a margin basis, LENZ Therapeutics, Inc. reports gross margins of 97.8%, compared to 71.5% for the sector. The operating margin is -244.1% (sector: -66.1%). Net profit margin stands at -215.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LENZ Debt, Balance Sheet, and Financial Health

LENZ Therapeutics, Inc. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.23x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $25M.

LENZ has a beta of 1.60, meaning it is more volatile than the broader market — a $10,000 investment in LENZ would be expected to move 59.7% more than the S&P 500 on any given day. The stability factor score for LENZ Therapeutics, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

LENZ Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, LENZ Therapeutics, Inc. reported revenue of $18M and earnings per share (EPS) of $-2.85. Net income for the quarter was $-56M. Gross margin was 97.8%. Operating income came in at $-66M.

In FY 2025, LENZ Therapeutics, Inc. reported revenue of $19M and earnings per share (EPS) of $-2.85. Net income for the quarter was $-82M. Gross margin was 97.8%. Operating income came in at $-91M.

In Q3 2025, LENZ Therapeutics, Inc. reported revenue of $13M and earnings per share (EPS) of $-0.59. Net income for the quarter was $-17M. Operating income came in at $-19M.

In Q2 2025, LENZ Therapeutics, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.53. Net income for the quarter was $-15M. Operating income came in at $-17M.

Over the past 8 quarters, LENZ Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $18M. Investors analyzing LENZ stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LENZ Dividend Yield and Income Analysis

LENZ Therapeutics, Inc. (LENZ) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LENZ Momentum and Technical Analysis Profile

LENZ Therapeutics, Inc. (LENZ) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

LENZ vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, LENZ Therapeutics, Inc. (LENZ) ranks #798 out of 838 stocks based on the Blank Capital composite score. This places LENZ in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LENZ against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LENZ vs S&P 500 (SPY) comparison to assess how LENZ Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

LENZ Next Earnings Date

No upcoming earnings date has been announced for LENZ Therapeutics, Inc. (LENZ) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LENZ? — Investment Thesis Summary

The quantitative profile for LENZ Therapeutics, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 21/100) increases portfolio risk.

In summary, LENZ Therapeutics, Inc. (LENZ) earns a Avoid rating with a composite score of 20.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LENZ stock.

Related Resources for LENZ Investors

Explore more research and tools: LENZ vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LENZ head-to-head with peers: LENZ vs AZN, LENZ vs SLGL, LENZ vs VMD.